Anil Melathe

Anil Melathe is a seasoned professional in oncology marketing with significant experience at Merck since February 2021, where roles include Director of US Oncology Marketing focusing on Early Stage NSCLC and Pan-Tumor HCP Marketing, with a concentration on KEYTRUDA (pembrolizumab) Life Cycle Management. Prior to Merck, Anil Melathe held positions at Bayer Pharmaceuticals from July 2019 to February 2021, working in US Oncology HCP Marketing for Prostate Cancer and Hepatocellular Carcinoma, specifically with NUBEQA (darolutamide), NEXAVAR (sorafenib), and STIVARGA (regorafenib). Additionally, Anil Melathe served as an Adjunct Faculty member at Rutgers University from 2019 to 2021. Academically, Anil Melathe earned a Bachelor of Arts in Biological Sciences from the University of Delaware, a Doctor of Pharmacy from the University at Buffalo, and completed a Post-Doctoral Fellowship at Rutgers University.